含G-CSF预激的化疗在难治/复发性急性白血病治疗中的研究进展  

Recent Advances of G-CSF Priming in Chemotherapy for Refractory or Recurrent Acute Leukemia

作　　者：沈照华[1] 曾东风[1] 孔佩艳[1] 

机构地区：[1]第三军医大学新桥医院血液科,重庆400037

出　　处：《肿瘤防治研究》2015年第5期526-530,共5页Cancer Research on Prevention and Treatment

摘　　要：难治与复发急性白血病(acute leukemia,AL)是白血病治疗中的最棘手的问题,患者病情进展迅速,并且难以治愈,且容易复发,甚至危及生命。近年来,多种化疗药物的联合给药方案,在AL的治疗中,取得了较好的临床疗效。含细胞因子的预激化疗方案能够动员处于静止期的白血病细胞进入细胞周期,增强化疗药物特别是周期特异性药物的杀伤作用,提高化疗缓解率,清除白血病微小残留病灶。笔者就含G-CSF预激的化疗在难治/复发性AL治疗中的应用作一综述。Refractory or recurrent acute leukemia(AL) is the most difficult problem in the leukemia treatment, with rapid disease progress, difficult to cure, easy to relapse and even threaten patients’ life. In recent years, the combination of various chemotherapy drugs has achieved good clinical effects in the treatment for AL. Chemotherapy regimens containing cytokines priming could make leukemia cells in the stationary stage mobilize into the S phase, enhance the killing effect of chemotherapeutic drugs, especially cycle-specific agent, increase the remission rate of chemotherapy and remove minimal residual disease. This paper reviews on the recent advances of the chemotherapy containing G-CSF priming for refractory or recurrent AL.

关 键 词：急性白血病 难治/复发 粒细胞集落刺激因子 预激 

分 类 号：R733.71[医药卫生—肿瘤]